Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D 0001906837 XXXXXXXX LIVE Common Stock, $0.0001 par value 10/19/2026 false 0002143850 178782108 City Therapeutics, Inc. 399 Binney Street Cambridge MA 02142 Mark McDonnell (773) 380 6600 ARCH Venture Management, LLC 8755 W. Higgins Road, Suite 1025 Chicago IL 60631 0001906837 N ARCH Venture Fund XII, L.P. WC N DE 0 13692507 0 13692507 13692507 N 25.6 PN 0001979765 N ARCH Venture Partners XII, L.P. WC N DE 0 13692507 0 13692507 13692507 N 25.6 PN 0001979548 N ARCH Venture Partners XII, LLC AF N DE 0 13692507 0 13692507 13692507 N 25.6 OO 0001219042 N Robert Nelsen AF N X1 0 13692507 0 13692507 13692507 N 25.6 IN 0001219039 N Keith Crandell AF N X1 0 13692507 0 13692507 13692507 N 25.6 IN 0001569248 N Kristina Burow AF N X1 0 13692507 0 13692507 13692507 N 25.6 IN 0001229592 N Steven Gillis AF N X1 0 13692507 0 13692507 13692507 N 25.6 IN Common Stock, $0.0001 par value City Therapeutics, Inc. 399 Binney Street Cambridge MA 02142 This statement relates to the Common Stock, $0.0001 par value (the "Common Stock"), of City Therapeutics, Inc. (the "Issuer") having its principal executive office at 399 Binney Street, Cambridge, MA 02142. This statement is being filed by (1) ARCH Venture Fund XII, L.P. ("AVF XII"), (2) ARCH Venture Partners XII, L.P. ("AVP XII LP") which is the sole general partner of AVF XII, (3) ARCH Venture Partners XII, LLC ("AVP XII LLC") which is the sole general partner of AVP XII LP, (4) Keith Crandell ("Crandell"), (5) Robert Nelsen ("Nelsen"), (6) Kristina Burow ("Burow"), and (7) Steven Gillis ("Gillis"). Nelsen, Crandell, Burow, and Gillis are referred to collectively as the "AVP XII Investment Committee Members". Each of the individuals and entities above shall be referred to herein as a "Reporting Person" and collectively as the "Reporting Persons." The business address of each of the Reporting Persons is 8755 West Higgins Road, Suite 1025, Chicago, IL, 60631. The principal business of AVP XII LP is to act as the general partner of AVF XII and the principal business of AVP XII LLC is to act as the general partner of AVP XII LP. AVP XII Investment Committee Members act as investment committee members of AVP XII LLC, and as managing directors or investment committee members of a number of affiliated partnerships with similar businesses. During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding. During the five years prior to the date hereof, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. AVF XII and AVP XII LP are limited partnerships organized under the laws of the State of Delaware. AVP XII LLC is a limited liability company organized under the laws of the State of Delaware. Each AVP XII Committee Member is a US citizen. On May 20, 2026, AVF XII purchased 2,027,006 shares of Series B Preferred Stock of the Issuer at a purchase price of $13.3201 per share. The number of shares reflects a 1.0983 for 1 stock split effected immediately prior to the closing of the initial public offering of the Issuer (the "IPO"). Each share of Series B Preferred Stock automatically converted into one share of the Issuer's Common Stock at the closing of the IPO. On October 19, 2026, AVF XII purchased 170,000 shares of Common Stock at a purchase price of $18.00 per share from the underwriters of the IPO. The source of funds for each of the purchases described in this Item 3 was the working capital of AVF XII. No part of the purchase price paid by AVF XII was represented by funds or other consideration borrowed or otherwise obtained for the purpose of acquiring, holding, trading or voting the shares of Common Stock described above. The total amount paid by for securities purchased in the above-listed transactions is as follows: AVF XII: $30,059,985.76 AVF XII and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF XII and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. AVF XII is the record owner of 13,692,507 shares of Common Stock ("AVF XII Record Shares"). AVP XII LP, as the sole general partner of AVF XII LP, may be deemed to beneficially own the AVF XII Record Shares. AVP XII LLC, as the sole general partner of AVP XII LP, may be deemed to beneficially own the AVF XII Record Shares. By virtue of their relationship as affiliated entities who have overlapping general partners and investment committee members, each of the AVP XII Investment Committee Members and direct and indirect general partners of AVF XII may be deemed to share the power to direct the AVF XII Record Shares. Each Reporting Person disclaims beneficial ownership of the Record Shares except for the shares, if any, held of record by such Reporting Person. The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated based on the 53,387,834 shares outstanding following the IPO, including full exercise of the underwriters' option, as reported by the Issuer in its Prospectus filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission on October 16, 2026. Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets. (ii) shared power to vote or to direct the vote: See line 8 of cover sheets. (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets. (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets. Except as set forth above, none of the Reporting Persons has effected any transaction in the Common Stock during the last 60 days. No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, shares beneficially owned by any of the Reporting Persons. Not applicable. AVF XII is party to that certain Amended and Restated Investors' Rights Agreement, dated May 20, 2026 (the "Investor Rights Agreement"). Pursuant to the Investor Rights Agreement, the Issuer has granted to AVF XII demand, piggyback and shelf registration rights with respect to shares of Common Stock held by AVF XII. Such registration rights will terminate upon the earlier of (i) the closing of a "Deemed Liquidation Event," as such term is defined in our certificate of incorporation (as currently in effect), (ii) the fifth anniversary of the completion of this offering and (iii) such time after consummation of this offering as SEC Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the securities subject to such registration rights without limitation during a three-month period without registration. Effective as of the closing of the IPO, the covenants relating to delivery of financial statements, inspection rights, and observer rights set forth in Section 3 and the rights of first offer were terminated. The foregoing description of the Investor Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 2 to this Schedule 13D and is incorporated herein by reference. AVF XII has entered into a lock-up agreement with the underwriters of the IPO (the "Lock-Up Agreement") pursuant to which AVF XII has agreed, subject to certain exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock for a period of 180 days after October 15, 2026, except with the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC, subject to certain exceptions. The foregoing description of the Lock-Up Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, the form of which is filed as Exhibit 3 to this Schedule 13D and is incorporated herein by reference. Exhibit 1- Agreement of Joint Filing Exhibit 2- Amended and Restated Investors' Rights Agreement, dated May 20, 2026, as amended, by and among the Issuer and certain of its stockholders (incorporated by reference to Exhibit 4.2 to the Issuer's Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission on October 9, 2026). Exhibit 3- Form of Lock-Up Agreement (incorporated by reference to Annex II to the Form of Underwriting Agreement filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A, filed with the Securities and Exchange Commission on October 9, 2026). ARCH Venture Fund XII, L.P. ARCH Venture Partners XII, L.P. its General Partner 10/26/2026 ARCH Venture Partners XII, LLC its General Partner 10/26/2026 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/26/2026 ARCH Venture Partners XII, L.P. ARCH Venture Partners XII, LLC its General Partner 10/26/2026 /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/26/2026 ARCH Venture Partners XII, LLC /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell, Managing Director 10/26/2026 Robert Nelsen /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Robert Nelsen 10/26/2026 Keith Crandell /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Keith Crandell 10/26/2026 Kristina Burow /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Kristina Burow 10/26/2026 Steven Gillis /s/ Mark McDonnell* Mark McDonnell, as Attorney-in-Fact for Steven Gillis 10/26/2026 *This Schedule 13D was executed by Mark McDonnell pursuant to a Power of Attorney filed as Exhibit 24.2 to the Form 3 relating to the beneficial ownership of shares of Neumora Therapeutics, Inc. by the Reporting Persons filed with the Securities Exchange Commission on September 14, 2023 and incorporated herein in its entirety by reference.